UEGW 2020 | Corticosteroids but not TNF-inhibitors increase severe COVID-19 outcomes risk
Ryan Ungaro reports results from the updated SECURE-IBD registry looking at the impact patient characteristics and immunosuppressants have on COVID-19 outcomes in patients with IBD (5:45).
UEGW 2020 | Treat-to-target aids ustekinumab dosing in patients with Crohn’s disease
Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).
UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis
Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).
UEGW 2020 | Ultraproactive therapeutic drug monitoring does not outperform reactive in IBD
Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).
